BOSTON, Oct. 14 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. is pleased to announce that the Company has taken the initial steps to obtain the CE Mark for its Food and Drug Administration (FDA) approved MammoView(TM) line of surgical endoscopy instruments. This will allow the MammoView(TM) line to be sold throughout the European Economic Union (EEU). The entire Solos Endoscopy product line has already received FDA approval for sale within the U.S. and the Company is now working diligently to capture market share within the EEU. According to a 2009 report published by Frost & Sullivan, the EEU represents $94 Billion, or 30%, of the worldwide demand for medical instruments.
Solos Endoscopy is working closely with its manufacturers to ensure all requirements of the Medical Devices Directive (MDD 93/42/EEC) are met. The Company is familiar with the steps that are to be taken to obtain the CE Mark for its MammoView(TM) line of surgical endoscopy instruments, as all of the Company’s other medical devices have already obtained the CE Mark. Solos Endoscopy is currently in discussions with several companies, to act as its Authorized Representatives (EC REP) to liaison with its targeted European markets.
“Expanding into the EEU provides unlimited sales opportunities for Solos Endoscopy and our goal is to commence sales, within several European countries, in 2010,” stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos’ sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company’s website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
